Results 171 to 180 of about 184,415 (251)

Pustular reaction in adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies. [PDF]

Front Immunol
Julanon N, Danpanichkul P, Choonhakarn C, Chaowattanapanit S, Anunnatsiri S, Chetchotisakd P, Kiratikanon S, Rujiwetpongstorn R, Tovanabutra N, Chiewchanvit S, Chaiwarith R, Phinyo P, Chuamanochan M.   +12 more
europepmc   +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Cost-effectiveness of latent tuberculosis infection screening using interferon-gamma release assays among migrants to Japan: a Markov modelling study incorporating social vulnerability and access barriers. [PDF]

BMJ Open
Kowada A.
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial. [PDF]

BMJ Open
Hernandez Padilla AC, Daix T, Hotchkiss RS, Monneret G, Tadie JM, Jeannet R, Plateker O, Vaidie J, Durand-Zaleski I, Magne J, Giraudeau B, François B.   +11 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Cutaneous Opportunistic Mycobacterial and Fungal Infections in Adult-Onset Immunodeficiency Due to Anti-Interferon-Gamma Autoantibodies-Decoding Skin Involvement Patterns. [PDF]

Open Forum Infect Dis
Rujiwetpongstorn R, Pinyo P, Prinyaroj N, Chaiwarith R, Kiratikanon S, Tovanabutra N, Chiewchanvit S, Choonhakarn C, Chaowattanapanit S, Chuamanochan M, Meesing A.   +10 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Diagnostic accuracy of interferon-gamma release assay and mucosal-associated invariant T cells in spinal tuberculosis. [PDF]

Sci Rep
Mekariya K, Ayutthaya PSN, Naowanirut A, Wongsa A, Tassaneetrithep B, Tantibhedhyangkul W, Ngamskulrungroj P, Muangsomboon S, Cheiwvit P, Wilartratsami S, Luksanapruksa P, Danchaivijitr N, Boonchai K, Rattanatanasarn A, Ruangchainikom M.   +14 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source